Global Preimplantation Genetic Testing Market Size study, By Product & Service (Reagents & Consumables, Instruments, Software & Services), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization

Global Preimplantation Genetic Testing Market Size study, By Product & Service (Reagents & Consumables, Instruments, Software & Services), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Single Nucleotide Polymorphism (SNP)), By Procedure Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), By Application (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, HLA Typing, Gender Identification), By End User (Maternity Centers & Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers, Research Laboratories & Academic Institutes), and Regional Forecasts 2022-2028

Global Preimplantation Genetic Testing Market is valued approximately USD 492.53 million in 2021 and is anticipated to grow with a healthy growth rate of more than 10.0% over the forecast period 2022-2028.

Pre-implantation genetic testing is the method that is used for the genetic analysis of embryos before implantation. It is a significant procedure because of rising cases of genetically imbalanced structures found in newborns and children. This method tests an embryo prior to implants for a particular, acknowledged genetic disorder. The increasing number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and the growing public-private investments in the field of preimplantation genetic testing are the primary factors that are augmenting the market growth. In addition, the declining fertility rate, coupled with the rising incidences of chromosomal abnormalities with proceeding maternal age is the further factor that is surging the market demand across the globe. For instance, according to the World Bank, the fertility rate per total birth worldwide was accounted with 2.445 in 2016 and the amount is declined to 2.402 in 2019. Therefore, decreasing fertility rate is anticipated to fuels the preimplantation genetic testing demand, which, in turn, impels the market growth. However, the high procedural cost associated with preimplantation genetic testing and unfavorable government regulations impedes the growth of the market over the forecast period of 2022-2028. Also, growing awareness of assisted reproduction techniques and increasing medical tourism are anticipated to act as a catalyzing factor for the market demand during the estimated years.


The key regions considered for the global Preimplantation Genetic Testing market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the increasing adoption of genomic techniques and growing need for IVF procedures (with decreasing fertility rates). Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as rising developments in healthcare infrastructure, as well as the rising focus of leading players on emerging markets, would create lucrative growth prospects for the Preimplantation Genetic Testing market across the Asia-Pacific region.

Major market players included in this report are:
Illumina, Inc.
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
PerkinElmer, Inc.
CooperSurgical, Inc.
Beijing Genomics Institute (BGI)
Abbott Laboratories Inc.
Natera, Inc.
Good Start Genetics, Inc.
Yikon Genomics Co., Ltd.


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product & Service:
Reagents & Consumables
Instruments
Software & Services
By Technology:
Next Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Fluorescent In-Situ Hybridization (FISH)
Comparative Genomic Hybridization (CGH)
Single Nucleotide Polymorphism (SNP)
By Procedure Type:
Preimplantation Genetic Screening
Preimplantation Genetic Diagnosis
By Application:
Aneuploidy
Structural Chromosomal Abnormalities
Single Gene Disorders
X-linked Disorders
HLA Typing
Gender Identification
By End User:
Maternity Centers & Fertility Clinics
Hospitals, Diagnostic Labs, and Service Providers
Research Laboratories & Academic Institutes
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Preimplantation Genetic Testing Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors







Companies Mentioned

Illumina, Inc.
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
PerkinElmer, Inc.
CooperSurgical, Inc.
Beijing Genomics Institute (BGI)
Abbott Laboratories Inc.
Natera, Inc.
Good Start Genetics, Inc.
Yikon Genomics Co., Ltd. Show more